Illumina Balance Sheet Health
Financial Health criteria checks 4/6
Illumina has a total shareholder equity of $5.7B and total debt of $1.5B, which brings its debt-to-equity ratio to 25.9%. Its total assets and total liabilities are $10.1B and $4.4B respectively.
Key information
25.9%
Debt to equity ratio
US$1.49b
Debt
| Interest coverage ratio | n/a |
| Cash | US$1.05b |
| Equity | US$5.75b |
| Total liabilities | US$4.37b |
| Total assets | US$10.11b |
Recent financial health updates
Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?
Jan 26
Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?
Oct 24Illumina (NASDAQ:ILMN) Is Carrying A Fair Bit Of Debt
Jun 13Is Illumina (NASDAQ:ILMN) Using Too Much Debt?
Mar 14These 4 Measures Indicate That Illumina (NASDAQ:ILMN) Is Using Debt Reasonably Well
Oct 27Recent updates
Calculating The Fair Value Of Illumina, Inc. (NASDAQ:ILMN)
Apr 26Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)
Mar 20Illumina: Stagnant Revenues And Shrinking Margins Amidst Rising Competition
Feb 23Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?
Jan 26Illumina: Volatility Galore, But Not Much Prospect Of Progress In 2024
Jan 19Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%
Dec 21Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?
Dec 03Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?
Oct 24Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?
Oct 03At US$167, Is Illumina, Inc. (NASDAQ:ILMN) Worth Looking At Closely?
Aug 22The Big Trends: New Frontiers in Healthcare
Jul 13
Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)
Jul 03Illumina (NASDAQ:ILMN) Is Carrying A Fair Bit Of Debt
Jun 13Is It Time To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?
Apr 12Is Illumina (NASDAQ:ILMN) Using Too Much Debt?
Mar 14Are Investors Undervaluing Illumina, Inc. (NASDAQ:ILMN) By 38%?
Dec 30Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$221?
Dec 02These 4 Measures Indicate That Illumina (NASDAQ:ILMN) Is Using Debt Reasonably Well
Oct 27Illumina, GenoScreen collaborate on genomic testing for drug-resistant TB
Oct 18Illumina in research collaboration with AstraZeneca on drug target discovery
Oct 11Illumina Engages Obama To Push Its Customers' Reimbursement Agenda
Sep 29Illumina to appeal EU decision to block GRAIL acquisition
Sep 06Illumina Needs Grail, But May Lose It
Aug 30Illumina added to positive catalyst watch at Citi despite Q2 miss
Aug 22Illumina up 9% following drop after Q2 earnings
Aug 15Is It Too Late To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?
Aug 08Still Avoiding Illumina Stock
Aug 05Illumina, Grail deal unlikely to get EU nod – Reuters
Jul 27Is Illumina, Inc. (NASDAQ:ILMN) Trading At A 48% Discount?
Jul 22Financial Position Analysis
Short Term Liabilities: ILMN's short term assets ($2.6B) exceed its short term liabilities ($1.6B).
Long Term Liabilities: ILMN's short term assets ($2.6B) do not cover its long term liabilities ($2.8B).
Debt to Equity History and Analysis
Debt Level: ILMN's net debt to equity ratio (7.6%) is considered satisfactory.
Reducing Debt: ILMN's debt to equity ratio has reduced from 44.2% to 25.9% over the past 5 years.
Debt Coverage: ILMN's debt is well covered by operating cash flow (32.1%).
Interest Coverage: Insufficient data to determine if ILMN's interest payments on its debt are well covered by EBIT.